VLX-1005 - Business-News-Today.com

🧬 Interested in pharma, biotech and medical device news? Visit PharmaDeviceNews.com →

Business news, market intelligence, and global industry analysis.

The Latest

Acumen Pharmaceuticals faces strategic reset with $78.6m cash after Alzheimer’s drug failure

NRx Pharmaceuticals moves toward ketamine sales after FDA approval of domestic injectable product

Intellect Design Arena (INTELLECT) near Rs 505: Is the 16% share-price crash justified when AI revenue is growing but profits are not?

Affle 3i to acquire Perion for $420m, but its $228m cash balance changes the deal maths

Read More

Pharma Industry News

CVKD expands clinical pipeline with acquisition of VLX-1005, a Phase 2 12-LOX inhibitor for HIT patients

Discover how Cadrenal Therapeutics’ acquisition of VLX-1005 could reshape treatment options for heparin-induced thrombocytopenia and strengthen its anticoagulation pipeline.

bySoujanya Ravi

December 13, 2025

web analytics